Marios Myronakis

Dr. Marios Myronakis

orcid

Research Focus & Metrics

Representative Publications

View All Publications
3 December 2023 in Physica Medica
Verified
Journal Article
Closed access
ETEleftherios Tzanis
Eleftherios Tzanis
JSJohn Stratakis
John Stratakis
MMMarios Myronakis
Marios Myronakis
JDJohn Damilakis
John Damilakis

29 May 2024 in Physica Medica
Verified
Journal Article
Closed access
TBTheocharis Berris
Theocharis Berris
MMMarios Myronakis
Marios Myronakis
JSJohn Stratakis
John Stratakis
KPKostas Perisinakis
Kostas Perisinakis
AKApostolos Karantanas
Apostolos Karantanas
JDJohn Damilakis
John Damilakis

5 February 2024 in Physica Medica
Verified
Journal Article
Closed access
FTFereniki Tsironi
Fereniki Tsironi
MMMarios Myronakis
Marios Myronakis
JSJohn Stratakis
John Stratakis
VSVarvara Sotiropoulou
Varvara Sotiropoulou
JDJohn Damilakis
John Damilakis

2 June 2026 in Cancers
Verified
Journal Article
Open access
PDF file
AGAngeliki Gkikoudi
Angeliki Gkikoudi
STSotiria Triantopoulou
Sotiria Triantopoulou
EMEygenia Markellou
Eygenia Markellou
VXVasiliki Xynou
Vasiliki Xynou
SVSpyridon N. Vasilopoulos
Spyridon N. Vasilopoulos
ALEXANDROS GEORGAKILASALEXANDROS GEORGAKILAS
ALEXANDROS GEORGAKILAS
Background: Radiotherapy outcomes are determined by the balance between tumor control and normal tissue toxicity, both of which exhibit significant interpatient variability. While radiogenomic and molecular approaches have identified determinants of radiosensitivity, their predictive performance remains limited when used in isolation. Methods: This review provides a comprehensive synthesis of functional assays, genomic biomarkers, and integrative models used to assess radiosensitivity, including radiation-induced lymphocyte apoptosis (RILA), chromosomal radiosensitivity assays, micronucleus formation, γ-H2AX foci kinetics, comet assays, clonogenic survival, and patient-derived organoids, alongside genomic and molecular predictors of tumor response such as hypoxia signatures and gene expression-based models (e.g., RSI and GARD). Results: Functional assays provide direct phenotypic assessment of radiation response, capturing DNA repair capacity, chromosomal stability, apoptosis, and tissue regenerative potential, and have shown associations in several studies with normal tissue toxicity across clinical settings. Tumor radiosensitivity is influenced by intrinsic cellular factors and microenvironmental conditions, including hypoxia and genomic instability. Integrative approaches combining functional, genomic, and clinical data show increasing potential for improving predictive accuracy. Conclusions: Radiosensitivity should be considered a systems-level phenotype requiring multi-dimensional assessment. Conceptual frameworks that integrate tumor and normal tissue responses within a unified modeling approach, supported by measurable biological and clinical parameters, represent a promising direction for clinically actionable precision radiotherapy. The integration of functional assays with genomic and clinical modeling frameworks represents a promising strategy for advancing personalized radiotherapy and improving therapeutic outcomes.

7 June 2016 in Medical Physics
Verified
Journal Article
Closed access
JRJ Rottmann
J Rottmann
MMMarios Myronakis
Marios Myronakis
YHY Hu
Y Hu
DSD Shedlock
D Shedlock
AWA Wang
A Wang
RBR Berbeco
R Berbeco